PSI Advisors’s Sarepta Therapeutics SRPT Stock Holding History

PSI Advisors’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-540	Closed	-$69K	–	520
2019 Q4	$69K	Buy	+540	New	+$54.5K	0.04%	232

Other funds holding SRPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

PSI Advisors's SRPT Position: Q1 2020 in Review

PSI Advisors sold out of Sarepta Therapeutics (SRPT) in Q1 2020, closing a stake of 540 shares — an estimated $69K sold.

PSI Advisors first reported a position in SRPT in Q4 2019 and held it in 1 quarter. The position peaked at $69K in Q4 2019. 365 funds tracked by Wall St. Rank hold SRPT as of Q1 2020.

PSI Advisors reported no remaining Sarepta Therapeutics position as of Q1 2020 after selling out during the quarter.
PSI Advisors sold 540 Sarepta Therapeutics shares in Q1 2020, an estimated $69K.
PSI Advisors first reported a position in Sarepta Therapeutics in Q4 2019 and held it in 1 quarter.
PSI Advisors's Sarepta Therapeutics position peaked at $69K in Q4 2019.
365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2020.

Based on PSI Advisors's 13F filing for Q1 2020, filed 15 May 2020.